Cramer Remix: 30 years later this is still a buy ·CNBC
Abigail Stevenson
Updated
Jim Cramer watched as the market was driven down on Monday by worried investors that feared the power of Amazon (NASDAQ: AMZN), especially on Cyber Monday. Even Cramer himself was concerned, and found the action very disconcerting.
When he heard that Amazon could be growing its sales double digit year-over-year, he interpreted that as being a negative trend for everyone else.
"There is simply no way that one retailer could see such an enormous uptick without it being zero-sum, meaning Amazon's gain is somebody else's pain," the "Mad Money" host said. (Tweet This)
With this in mind, Cramer decided to dig deep to find the stocks that simply cannot be 'Amazon-ed.' These are companies that offer such a great value proposition, that they are even worth buying on a day like Monday with almost every retailer was down.
Cramer selected Costco (NASDAQ: COST), because it makes its real money from the membership card. He also liked Ulta Salon (NASDAQ: ULTA), because even with snazzy drones — Amazon can't do your hair. It will never have the beauty parlors that Ulta has, thus Ulta cannot be Amazon-ed.
Third was TJX (NYSE: TJX), which has been a huge beneficiary of the excess inventory at major department stores. Next was Home Depot (NYSE: HD), as these days more people are investing in their homes and shopping at Home Depot. His last pick was Dollar Tree (NASDAQ: DLTR), which reported a strong quarter last week.
Another stock that Cramer recommended was Kimberly Clark, which he recommended over 30 years ago and still thinks is a buy.
Last week, Cramer found some puzzling news in the jewelry group. Signet, the parent company of Kay Jewelers, Jared and Zales, reported its first weaker than expected quarter in a long time and the stock was slammed, falling to $134 from $140 last Tuesday.
At the same time, Tiffany, the major international jewelry company with a stock that has been a total dog all year, delivered a mixed earnings report and its stock rallied on the news.
A little over a month ago, Cramer recommended Signet as a relatively unknown jewelry play that seemed ready to roar because of its acquisition in Zales.
"Fast forward to today and clearly I got that Signet call all wrong, given that the stock has fallen from $147, where I recommended it in late October, down to $130 as of today. So mea culpa," Cramer said.
However, that doesn't mean that investors should run away from Signet. In fact, Cramer thinks it is now more attractive at $130, especially since people don't buy engagement rings on Amazon. So despite Signet's disappointment last week, he's still not ready to change his opinion.
Cramer has always believed in the power of a CEO. A good chief can turn around a company, but a bad one can run even the best companies into the ground.
"Sometimes having no CEO is better than having a truly terrible chief executive," the "Mad Money" host said. (Tweet This)
This was evident when Cramer examined the case of teen retailer Abercrombie & Fitch (NYSE: ANF). It reported a fantastic quarter a little over a week ago, which sent the stock soaring 25 percent in one session. But what Cramer found most impressive about its results was that it did all of this without a permanent CEO.
In fact, former CEO Mike Jeffries retired nearly a year ago —and the company is doing better for the first time in ages.
Last week, Cramer learned that the much-discussed merger betweenAllergan (NYSE: AGN) and Pfizer (NYSE: PFE) is really happening. This would create the world's largest pharmaceutical deal, with $160 billion in an all stock transaction.
The deal stipulated that Allergan shareholders would receive 11.3 shares of Pfizer for every one share of Allergan.
"Even though I think this is a very smart deal, one that will give Pfizer a tremendous pipeline of new drugs along with a lower Irish corporate tax rate, the market initially seemed pretty skeptical," the "Mad Money" host said.
Yet many questions remain on how the transaction will reward Allergan shareholders, given how much the company already has going for it on its own. That is why Cramer decided to go straight to the source, and spoke with Allergan's CEO Brent Saunders.
"I think it's a great opportunity for our shareholders," Saunders told the "Mad Money" host. "The way I like to think about it, it is taking our growth pharma engine and put it on a larger chassis called Pfizer. Look, we could have gone to $400 [dollars per share] on our own, but this takes us well beyond that for the foreseeable future."
For those investors that want to understand today's economy, Cramer says to take into consideration that the Pittsburgh Steelers are now worth almost twice as much as U.S. Steel.
At this moment Forbes Magazine values the football team at $1.9 billion. Yet the U.S. Steel company with more than 30,000 employees is only worth $1.1 billion, and the stock is down 70 percent for the year.
"Look, this is a real contrast — I'm not just trying to be silly. The United States produces some incredible entertainment and we do so in part by not diluting its value," Cramer said.
But the fact is that the world produces a massive amount of steel, and regardless of how good a company is at making the stuff, how low costs are, or where it's manufactured — there is excess supply.
Ultimately this group has been sacrificed, and Cramer thinks investor portfolios will also be sacrificed if they try to bottom fish in the stocks of these companies that cannot possibly compete in this new, unfair environment.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Arris Group, Inc: "Well it's done a lot of great stuff in the cable industry. I myself have always found that this is a company with inconsistent quarters, but it is in the sweet spot. I would not trade it right now, I would own it."
Eaton Corp: "Supported by the yield. The last couple of quarters were not that good, but 3.7 percent yield. If it goes to 4 percent I'm a buyer."
Read More Lightning Round: It's in the sweet spot now
